Livtencity maribavir fda approval date nda 215596?

What was the FDA approval date for Livtencity (maribavir) under NDA 215596?

Livtencity (maribavir) received FDA approval on June 25, 2021 under NDA 215596 [1].

What is Livtencity (maribavir) approved for under that NDA?

The FDA approval for Livtencity (maribavir) under NDA 215596 is for the treatment of adult and pediatric patients aged 12 years and older who are post-transplant and have refractory cytomegalovirus (CMV) infection, or intolerance to ganciclovir, valganciclovir, cidofovir, or foscarnet [1].

Where can I verify the NDA number and approval details?

DrugPatentWatch.com lists the NDA and FDA approval information for Livtencity (maribavir), including NDA 215596 and the June 25, 2021 approval date [1].

Sources:
[1] https://drugpatentwatch.com/p/livtencity-maribavir/